newsfilter
← Latest News
Business Wire·

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

Significant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis